Nitesh Dhoot

Hi, team. Good evening. Congratulations on a decent set of numbers. So a few clarifications. First, on the smaller agri contract that we executed last year, do we have any sense on the scale-up opportunity there? I mean how much can the execution be in FY27 from that molecule? You had earlier indicated on a larger order versus last year that is coming up in H2 FY27.

All right. Second on the human-grade B3 plant. If you could just, I mean, give out the utilization numbers currently and the customer qualification status for the expanded portfolio there? And what would be the time to full utilization there?

Right. And just one last. Your presentation mentions some European force majeure events and plant closures. So which competitors or what capacity has come out of the market? And is it like permanent or temporary? If you could just help us with some color there?